Lytix Biopharma completes patient recruitment for advanced melanoma trial
Lytix Biopharma, a clinical stage immuno-oncology company, has completed recruitment of 20 patients in its trial evaluating LTX-315, the company’s lead drug candidate.
Source: biopharma-reporter.com